Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 109-113

  Molife, L R ^a   Attard, G ^a   Fong, P C ^a   Karavasilis, V ^a   Reid, A H M ^a   Patterson, S ^b   Riggs, C E ^c   Higano, C ^d   Stadler, W M ^e   McCulloch, W ^f   Dearnaley, D ^a   Parker, C ^a   de Bono, J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Gloucester Pharmaceuticals   (United States)

Author keywords

Histone deacetylase; Phase II; Prostate cancer; Romidepsin

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ROMIDEPSIN;

ADULT; ANOREXIA; ANTIGEN DETECTION; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER STAGING; CARDIOTOXICITY; CASTRATED MALE; CATHETER INFECTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; ELECTROLYTE DISTURBANCE; FATIGUE; HEART DISEASE; HEART VENTRICLE BIGEMINY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; SIDE EFFECT; SKIN DISEASE; ST SEGMENT; T WAVE INVERSION; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 70549105748     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp270     Document Type: Article

References (29)

1. Cancer Facts and Figures. American Cancer Society, Atlanta, GA 2007.
2. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-179.
3. Petrylak DP, Tangeb CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
4. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
5. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
6. Attard G, Reid A, Yap T et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer (CRPC) commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-4571.
7. De Bono JS, Attard G, Reid A et al. Anti-tumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer. J Clin Oncol 2008; 26 (Suppl): (Abstr 5005).
8. Marks P, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
9. Weichert W, Röske A, Gekeler V et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604-610.
10. Ueda H, Nakajima H, Yori Y et al. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994; 58: 1579-1583.
11. Sandor V, Senderowicz A, Mertins S et al. p21 dependent G(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83: 817-825.
12. Yu X, Guo ZS, Marcu MG et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94: 504-513.
13. Welsbie DS, Xu J, Chen Y et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009; 69: 958-966.
14. Fang Y, Fliss AE, Robins DM, Caplan AJ. Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 1996; 271: 28697-28702.
15. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 2003; 30: 709-716.
16. Fiskus W, Ren Y, Mohapatra A et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007; 13: 4882-4890.
17. Kovacs JJ, Murphy PJ, Gaillard S et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607.
18. de Bono J, Kristeleit R, Tolcher A et al. Phase I, pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with an HSP90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 6663-6673.
19. Marshall JL, Rizvi N, Kauh J et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002; 2: 325-332.
20. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728.
21. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
22. Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 12: 3762-3773.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
24. Chang MN, Therneau TM, Wieand HS, Cha SS. Designs for group sequential phase II clinical trials. Biometrics 1987; 43: 865-874.
25. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
26. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
27. Molife R, Fong P, Scurr M et al. HDAC inhibitors and cardiac safety. Clin Cancer Res 2006; 12: 3997-4003.
28. Steele N, Plumb JA, Vidal L et al. A phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 804-810.
29. Rathkopf DE, Wong BY, Ross RW et al. A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC). J Clin Oncol 2008; 26 (Suppl): (Abstr 5152).